Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2022-11, Vol.24 (11), p.2273-2276 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2276 |
|---|---|
| container_issue | 11 |
| container_start_page | 2273 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 24 |
| creator | Snitker, Søren Egebjerg, Christina Frederiksen, Marie Sparre, Thomas |
| description | |
| doi_str_mv | 10.1111/dom.14809 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9805145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2685446503</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4439-798837fcb9e6112cb21e19b687b1dc10acb8c2457892256ada128b1eb8b320c63</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhSMEoj-w4AWQJTawyNR2nMTZIFVlgJGKikRZW7Zzk_HIsUPsdDQ7HqGvwKvxJHg6pQIkvLCvfD-fe6yTZS8IXpC0zlo_LAjjuHmUHRNWFTkpaPX4rqY5bzA9yk5C2GCMWcHrp9lRUdYNqWh5nP1YygA_v9_6Lm1zACRdi6TWMEapjDVxh3yH4hqQ8zdgUYBB9naOpgVEFwwNPQrG9Xav0fr0fgSXSuM2oKOfkHHpxo8W0NbENUoa0xZMv44oNb2CsJ-QoP2EL9fLz4ijcZ0sodVqheJkpH2WPemkDfD8_jzNvr5fXl98zC-vPqwuzi9zzVjR5HXDeVF3WjVQEUK1ogRIoypeK9JqgqVWXFNW1ryhtKxkKwnlioDiqqBYV8Vp9vagO85qgFaDi5O0YpzMIKed8NKIvzvOrEXvb0TDcUlYmQRe3wtM_tsMIYrBBA3WSgd-DoJWvGSsKnGR0Ff_oBs_Ty59T9CaYlpUDDeJenOg9ORDmKB7MEOw2AcvUvDiLvjEvvzT_QP5O-kEnB2ArbGw-7-SeHf16SD5C-K0vL8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2720236409</pqid></control><display><type>article</type><title>Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Snitker, Søren ; Egebjerg, Christina ; Frederiksen, Marie ; Sparre, Thomas</creator><creatorcontrib>Snitker, Søren ; Egebjerg, Christina ; Frederiksen, Marie ; Sparre, Thomas</creatorcontrib><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.14809</identifier><identifier>PMID: 35791625</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antidiabetics ; antiobesity drug ; Body weight ; clinical trial ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Drug administration ; Drug therapy ; GLP‐1 analogue ; Glucagon-Like Peptides - therapeutic use ; Humans ; Hypoglycemic Agents ; Injections ; Obesity ; Obesity - complications ; Obesity - drug therapy ; obesity therapy ; Overweight ; Overweight - complications ; Overweight - drug therapy ; Patient satisfaction ; phase III study ; Research Letter ; Weight control</subject><ispartof>Diabetes, obesity & metabolism, 2022-11, Vol.24 (11), p.2273-2276</ispartof><rights>2022 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4439-798837fcb9e6112cb21e19b687b1dc10acb8c2457892256ada128b1eb8b320c63</citedby><cites>FETCH-LOGICAL-c4439-798837fcb9e6112cb21e19b687b1dc10acb8c2457892256ada128b1eb8b320c63</cites><orcidid>0000-0001-8313-6701</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.14809$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.14809$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35791625$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Snitker, Søren</creatorcontrib><creatorcontrib>Egebjerg, Christina</creatorcontrib><creatorcontrib>Frederiksen, Marie</creatorcontrib><creatorcontrib>Sparre, Thomas</creatorcontrib><title>Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><subject>Antidiabetics</subject><subject>antiobesity drug</subject><subject>Body weight</subject><subject>clinical trial</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Drug administration</subject><subject>Drug therapy</subject><subject>GLP‐1 analogue</subject><subject>Glucagon-Like Peptides - therapeutic use</subject><subject>Humans</subject><subject>Hypoglycemic Agents</subject><subject>Injections</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>obesity therapy</subject><subject>Overweight</subject><subject>Overweight - complications</subject><subject>Overweight - drug therapy</subject><subject>Patient satisfaction</subject><subject>phase III study</subject><subject>Research Letter</subject><subject>Weight control</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhSMEoj-w4AWQJTawyNR2nMTZIFVlgJGKikRZW7Zzk_HIsUPsdDQ7HqGvwKvxJHg6pQIkvLCvfD-fe6yTZS8IXpC0zlo_LAjjuHmUHRNWFTkpaPX4rqY5bzA9yk5C2GCMWcHrp9lRUdYNqWh5nP1YygA_v9_6Lm1zACRdi6TWMEapjDVxh3yH4hqQ8zdgUYBB9naOpgVEFwwNPQrG9Xav0fr0fgSXSuM2oKOfkHHpxo8W0NbENUoa0xZMv44oNb2CsJ-QoP2EL9fLz4ijcZ0sodVqheJkpH2WPemkDfD8_jzNvr5fXl98zC-vPqwuzi9zzVjR5HXDeVF3WjVQEUK1ogRIoypeK9JqgqVWXFNW1ryhtKxkKwnlioDiqqBYV8Vp9vagO85qgFaDi5O0YpzMIKed8NKIvzvOrEXvb0TDcUlYmQRe3wtM_tsMIYrBBA3WSgd-DoJWvGSsKnGR0Ff_oBs_Ty59T9CaYlpUDDeJenOg9ORDmKB7MEOw2AcvUvDiLvjEvvzT_QP5O-kEnB2ArbGw-7-SeHf16SD5C-K0vL8</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Snitker, Søren</creator><creator>Egebjerg, Christina</creator><creator>Frederiksen, Marie</creator><creator>Sparre, Thomas</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8313-6701</orcidid></search><sort><creationdate>202211</creationdate><title>Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial</title><author>Snitker, Søren ; Egebjerg, Christina ; Frederiksen, Marie ; Sparre, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4439-798837fcb9e6112cb21e19b687b1dc10acb8c2457892256ada128b1eb8b320c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antidiabetics</topic><topic>antiobesity drug</topic><topic>Body weight</topic><topic>clinical trial</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Drug administration</topic><topic>Drug therapy</topic><topic>GLP‐1 analogue</topic><topic>Glucagon-Like Peptides - therapeutic use</topic><topic>Humans</topic><topic>Hypoglycemic Agents</topic><topic>Injections</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>obesity therapy</topic><topic>Overweight</topic><topic>Overweight - complications</topic><topic>Overweight - drug therapy</topic><topic>Patient satisfaction</topic><topic>phase III study</topic><topic>Research Letter</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Snitker, Søren</creatorcontrib><creatorcontrib>Egebjerg, Christina</creatorcontrib><creatorcontrib>Frederiksen, Marie</creatorcontrib><creatorcontrib>Sparre, Thomas</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Snitker, Søren</au><au>Egebjerg, Christina</au><au>Frederiksen, Marie</au><au>Sparre, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2022-11</date><risdate>2022</risdate><volume>24</volume><issue>11</issue><spage>2273</spage><epage>2276</epage><pages>2273-2276</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>35791625</pmid><doi>10.1111/dom.14809</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-8313-6701</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2022-11, Vol.24 (11), p.2273-2276 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9805145 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antidiabetics antiobesity drug Body weight clinical trial Diabetes Diabetes Mellitus, Type 2 - drug therapy Drug administration Drug therapy GLP‐1 analogue Glucagon-Like Peptides - therapeutic use Humans Hypoglycemic Agents Injections Obesity Obesity - complications Obesity - drug therapy obesity therapy Overweight Overweight - complications Overweight - drug therapy Patient satisfaction phase III study Research Letter Weight control |
| title | Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A20%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ease%E2%80%90of%E2%80%90use%20and%20acceptability%20of%20the%20novel%20semaglutide%202.4%20mg%20single%E2%80%90dose%20pen%E2%80%90injector%20in%20people%20with%20overweight%20or%20obesity%20in%20the%20STEP%208%20phase%20III%20trial&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Snitker,%20S%C3%B8ren&rft.date=2022-11&rft.volume=24&rft.issue=11&rft.spage=2273&rft.epage=2276&rft.pages=2273-2276&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.14809&rft_dat=%3Cproquest_pubme%3E2685446503%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2720236409&rft_id=info:pmid/35791625&rfr_iscdi=true |